S&P 500   3,133.49 (+0.03%)
DOW   27,826.48 (-0.20%)
QQQ   204.25 (+0.17%)
AAPL   269.74 (+0.47%)
FB   200.99 (+0.06%)
MSFT   151.04 (-0.06%)
GOOGL   1,341.22 (-0.12%)
AMZN   1,738.34 (-0.05%)
NVDA   215.98 (+0.93%)
MU   48.90 (+3.03%)
BABA   203.41 (+1.48%)
TSLA   355.83 (+2.00%)
AMD   39.43 (-0.03%)
ACB   2.49 (-1.19%)
F   9.12 (+0.55%)
PRI   134.62 (-0.48%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.06 (+0.66%)
S&P 500   3,133.49 (+0.03%)
DOW   27,826.48 (-0.20%)
QQQ   204.25 (+0.17%)
AAPL   269.74 (+0.47%)
FB   200.99 (+0.06%)
MSFT   151.04 (-0.06%)
GOOGL   1,341.22 (-0.12%)
AMZN   1,738.34 (-0.05%)
NVDA   215.98 (+0.93%)
MU   48.90 (+3.03%)
BABA   203.41 (+1.48%)
TSLA   355.83 (+2.00%)
AMD   39.43 (-0.03%)
ACB   2.49 (-1.19%)
F   9.12 (+0.55%)
PRI   134.62 (-0.48%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.06 (+0.66%)
S&P 500   3,133.49 (+0.03%)
DOW   27,826.48 (-0.20%)
QQQ   204.25 (+0.17%)
AAPL   269.74 (+0.47%)
FB   200.99 (+0.06%)
MSFT   151.04 (-0.06%)
GOOGL   1,341.22 (-0.12%)
AMZN   1,738.34 (-0.05%)
NVDA   215.98 (+0.93%)
MU   48.90 (+3.03%)
BABA   203.41 (+1.48%)
TSLA   355.83 (+2.00%)
AMD   39.43 (-0.03%)
ACB   2.49 (-1.19%)
F   9.12 (+0.55%)
PRI   134.62 (-0.48%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.06 (+0.66%)
S&P 500   3,133.49 (+0.03%)
DOW   27,826.48 (-0.20%)
QQQ   204.25 (+0.17%)
AAPL   269.74 (+0.47%)
FB   200.99 (+0.06%)
MSFT   151.04 (-0.06%)
GOOGL   1,341.22 (-0.12%)
AMZN   1,738.34 (-0.05%)
NVDA   215.98 (+0.93%)
MU   48.90 (+3.03%)
BABA   203.41 (+1.48%)
TSLA   355.83 (+2.00%)
AMD   39.43 (-0.03%)
ACB   2.49 (-1.19%)
F   9.12 (+0.55%)
PRI   134.62 (-0.48%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.06 (+0.66%)
Log in

NASDAQ:EYEN - Eyenovia Stock Price, Forecast & News

$3.46
+0.02 (+0.58 %)
(As of 12/11/2019 12:42 PM ET)
Today's Range
$3.46
Now: $3.46
$3.46
50-Day Range
$2.68
MA: $3.27
$4.31
52-Week Range
$2.40
Now: $3.46
$6.98
Volume100 shs
Average Volume113,050 shs
Market Capitalization$56.88 million
P/E RatioN/A
Dividend YieldN/A
Beta1.42
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYEN
CUSIPN/A
Phone917-289-1117

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.43 per share

Profitability

Net Income$-17,250,000.00

Miscellaneous

EmployeesN/A
Market Cap$56.88 million
Next Earnings Date3/25/2020 (Estimated)
OptionableNot Optionable

Receive EYEN News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.


Eyenovia (NASDAQ:EYEN) Frequently Asked Questions

What is Eyenovia's stock symbol?

Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."

How were Eyenovia's earnings last quarter?

Eyenovia Inc (NASDAQ:EYEN) posted its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.34) by $0.05. View Eyenovia's Earnings History.

When is Eyenovia's next earnings date?

Eyenovia is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Eyenovia.

What price target have analysts set for EYEN?

2 brokerages have issued twelve-month price objectives for Eyenovia's stock. Their forecasts range from $9.00 to $10.00. On average, they anticipate Eyenovia's stock price to reach $9.50 in the next year. This suggests a possible upside of 178.6% from the stock's current price. View Analyst Price Targets for Eyenovia.

What is the consensus analysts' recommendation for Eyenovia?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyenovia.

What are Wall Street analysts saying about Eyenovia stock?

Here are some recent quotes from research analysts about Eyenovia stock:
  • 1. According to Zacks Investment Research, "Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc. is based in New York. " (12/3/2019)
  • 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $240M, which includes a discounted cash flow-based asset value for all four micro-dosing products, with a 15% discount rate and 1% terminal growth rate. Probabilities of success assigned are 80%, 75%, 55% and 45% for MicroPine, respectively." (2/14/2019)

Has Eyenovia been receiving favorable news coverage?

News articles about EYEN stock have trended somewhat positive this week, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eyenovia earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Eyenovia.

Are investors shorting Eyenovia?

Eyenovia saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 358,200 shares, an increase of 36.9% from the October 31st total of 261,700 shares. Based on an average daily volume of 73,300 shares, the short-interest ratio is presently 4.9 days. Approximately 3.7% of the company's shares are sold short. View Eyenovia's Current Options Chain.

Who are some of Eyenovia's key competitors?

What other stocks do shareholders of Eyenovia own?

Who are Eyenovia's key executives?

Eyenovia's management team includes the folowing people:
  • Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer & Director (Age 46)
  • Ms. Jennifer Clasby, VP of Clinical Operations (Age 65)
  • Mr. Luke Clauson, VP of R&D (Age 40)
  • Mr. John P. Gandolfo, CFO & Sec. (Age 58)
  • Mr. Michael M. Rowe, VP of Marketing

When did Eyenovia IPO?

(EYEN) raised $30 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ served as the underwriters for the IPO.

Who are Eyenovia's major shareholders?

Eyenovia's stock is owned by a number of of retail and institutional investors. Top institutional investors include Fairpointe Capital LLC (1.37%) and Sabby Management LLC (0.11%). Company insiders that own Eyenovia stock include Charles E Iv Mather, Curt H Labelle, Fredric N Eshelman, John P Gandolfo, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev. View Institutional Ownership Trends for Eyenovia.

Which institutional investors are selling Eyenovia stock?

EYEN stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for Eyenovia.

Which institutional investors are buying Eyenovia stock?

EYEN stock was acquired by a variety of institutional investors in the last quarter, including Fairpointe Capital LLC. Company insiders that have bought Eyenovia stock in the last two years include Charles E Iv Mather, Curt H Labelle, Fredric N Eshelman, John P Gandolfo, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev. View Insider Buying and Selling for Eyenovia.

How do I buy shares of Eyenovia?

Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eyenovia's stock price today?

One share of EYEN stock can currently be purchased for approximately $3.41.

How big of a company is Eyenovia?

Eyenovia has a market capitalization of $56.06 million. The company earns $-17,250,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. View Additional Information About Eyenovia.

What is Eyenovia's official website?

The official website for Eyenovia is http://www.eyenoviabio.com/.

How can I contact Eyenovia?

Eyenovia's mailing address is 295 Madison Avenue Suite 2400, New York NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected]


MarketBeat Community Rating for Eyenovia (NASDAQ EYEN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  261
MarketBeat's community ratings are surveys of what our community members think about Eyenovia and other stocks. Vote "Outperform" if you believe EYEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: Insider Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel